Akebia Therapeutics Inc (AKBA)
1.37
+0.01
(+0.74%)
USD |
NASDAQ |
Apr 22, 16:00
1.38
+0.01
(+0.73%)
After-Hours: 04:27
Akebia Therapeutics Cash from Investing (TTM): 0.00 for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 0.00 |
September 30, 2023 | 0.00 |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | -0.114M |
September 30, 2022 | -0.114M |
June 30, 2022 | -0.114M |
March 31, 2022 | 19.89M |
December 31, 2021 | 39.94M |
September 30, 2021 | 99.62M |
June 30, 2021 | 49.69M |
March 31, 2021 | -20.31M |
December 31, 2020 | -40.00M |
September 30, 2020 | -77.41M |
June 30, 2020 | -3.08M |
March 31, 2020 | 100.95M |
December 31, 2019 | 211.18M |
September 30, 2019 | 205.61M |
June 30, 2019 | 192.23M |
March 31, 2019 | 134.63M |
December 31, 2018 | 36.59M |
Date | Value |
---|---|
September 30, 2018 | 11.57M |
June 30, 2018 | -44.40M |
March 31, 2018 | -72.52M |
December 31, 2017 | -177.26M |
September 30, 2017 | -146.65M |
June 30, 2017 | -56.12M |
March 31, 2017 | 5.357M |
December 31, 2016 | 12.70M |
September 30, 2016 | -7.963M |
June 30, 2016 | -67.98M |
March 31, 2016 | -102.05M |
December 31, 2015 | -13.69M |
September 30, 2015 | -22.96M |
June 30, 2015 | -48.51M |
March 31, 2015 | -67.30M |
December 31, 2014 | -65.35M |
September 30, 2014 | -55.98M |
June 30, 2014 | -29.14M |
March 31, 2014 | -6.067M |
December 31, 2013 | -11.42M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-77.41M
Minimum
Sep 2020
211.18M
Maximum
Dec 2019
40.95M
Average
--
Median
Mar 2023
Cash from Investing (TTM) Benchmarks
Ocugen Inc | 3.077M |
Aquestive Therapeutics Inc | -0.995M |
SELLAS Life Sciences Group Inc | -- |
Protagonist Therapeutics Inc | -39.26M |
Stoke Therapeutics Inc | 105.95M |